Global Interventional Cardiology (IC) Reporting Unit — Net Sales
Boston Scientific Global Interventional Cardiology (IC) Reporting Unit — Net Sales decreased by 0.2% to $2.64B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 24.0%, from $2.13B to $2.64B. Over 3 years (FY 2021 to FY 2024), Global Interventional Cardiology (IC) Reporting Unit — Net Sales shows an upward trend with a 15.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong demand for the company's cardiac product portfolio and successful market adoption of new interventional technologies, while a decrease may signal increased competition, pricing pressure, or reduced procedure volumes.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and technologies specifically design...
Peer comparison
Comparable to cardiovascular segment revenues reported by major medical device peers like Medtronic or Abbott Laboratories, reflecting the core performance of heart-related medical technology divisions.
bsx_segment_cardiology_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.41B | $1.34B | $1.42B | $1.41B | $1.52B | $1.48B | $1.53B | $1.61B | $1.70B | $1.65B | $1.75B | $1.87B | $2.05B | $2.13B | $2.30B | $2.43B | $2.65B | $2.64B |
| QoQ Change | — | -4.8% | +6.0% | -1.1% | +7.8% | -2.5% | +3.4% | +5.0% | +6.1% | -3.3% | +6.4% | +6.8% | +9.3% | +4.0% | +7.8% | +5.8% | +9.0% | -0.2% |
| YoY Change | — | — | — | — | +7.6% | +10.2% | +7.5% | +14.1% | +12.3% | +11.4% | +14.6% | +16.6% | +20.1% | +29.3% | +31.1% | +29.8% | +29.3% | +24.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's global interventional cardiology (ic) reporting unit — net sales?
- Boston Scientific (BSX) reported global interventional cardiology (ic) reporting unit — net sales of $2.64B in Q3 2025.
- How has Boston Scientific's global interventional cardiology (ic) reporting unit — net sales changed year-over-year?
- Boston Scientific's global interventional cardiology (ic) reporting unit — net sales increased by 24.0% year-over-year, from $2.13B to $2.64B.
- What is the long-term trend for Boston Scientific's global interventional cardiology (ic) reporting unit — net sales?
- Over 3 years (2021 to 2024), Boston Scientific's global interventional cardiology (ic) reporting unit — net sales has grown at a 15.5% compound annual growth rate (CAGR), from $5.42B to $8.34B.
- What does global interventional cardiology (ic) reporting unit — net sales mean?
- Total revenue generated from the sale of cardiovascular medical devices and rhythm management technologies.